Asco 2023 preview – Tigit lives again
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Mirasol knockout puts the pressure on Sutro
Apparently knockout ovarian cancer data put Immunogen’s Elahere on track for full approval, a risk Sutro investors have decided to ignore.
Major readouts on the horizon for small developers
Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.
World ADC 2023 – targeting the folate receptor rises from the ashes
Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.
JP Morgan 2023 – Sutro makes its pitch to beat Immunogen
The group reckons it can target twice as many ovarian cancer patients, but an important disclosure shows that its case it not clear-cut.
Biotech’s key upcoming clinical results
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Not so fast for some accelerated approvals
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
